Share on StockTwits

Cardinal Health (NYSE:CAH) has been given a consensus recommendation of “Buy” by the nineteen ratings firms that are currently covering the stock, AR Network reports. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $77.93.

Shares of Cardinal Health (NYSE:CAH) opened at 73.0202 on Monday. Cardinal Health has a 52 week low of $49.65 and a 52 week high of $74.40. The stock’s 50-day moving average is $71.35 and its 200-day moving average is $69.68. The company has a market cap of $24.583 billion and a price-to-earnings ratio of 21.58.

Cardinal Health (NYSE:CAH) last released its earnings data on Monday, August 4th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.81 by $0.02. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $21.88 billion. During the same quarter last year, the company posted $0.79 earnings per share. Cardinal Health’s revenue was down 9.9% compared to the same quarter last year. On average, analysts predict that Cardinal Health will post $4.25 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a dividend of $0.3425 per share. This represents a $1.37 annualized dividend and a dividend yield of 1.88%. The ex-dividend date is Monday, September 29th.

In other Cardinal Health news, EVP Mark R. Blake sold 4,782 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $72.15, for a total value of $345,021.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Argus reiterated a “buy” rating on shares of Cardinal Health in a research note on Monday, August 18th. They now have a $71.43 price target on the stock, down previously from $83.00. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $82.00 price target on the stock, up previously from $77.00. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $80.00 price target on the stock, up previously from $76.00.

Cardinal Health, Inc is a healthcare services company providing pharmaceutical and medical products and services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.